Cartesian Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $387 | $33,445 | $5,840 | $8,266 |
Gross Profit | 387 | 33,249 | 5,657 | 7,994 |
EBITDA | -23,897 | 14,032 | -56,641 | -196,386 |
EBIT | -24,183 | 13,836 | -56,824 | -196,658 |
Net Income | -24,183 | 13,836 | -56,824 | -177,658 |
Net Change In Cash | 387 | 33,445 | 5,840 | 8,266 |
Free Cash Flow | 7,492 | -16,033 | -16,519 | -23,350 |
Cash | 219,198 | 87,227 | 103,418 | 76,911 |
Basic Shares | 7,157 | 17,791 | 5,414 | 5,160 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $26,004 | $110,777 | $85,077 | $16,597 |
Gross Profit | 24,451 | 108,740 | 85,077 | 16,597 |
EBITDA | -235,064 | 39,838 | -5,158 | -65,593 |
EBIT | -235,907 | 37,801 | -6,877 | -67,320 |
Net Income | -219,710 | 35,379 | -25,687 | -68,876 |
Net Change In Cash | 26,004 | 110,777 | 85,077 | 16,597 |
Cost of Revenue | -7,418 | -24,628 | 48,513 | |
Free Cash Flow | -51,367 | -32,832 | -61,467 | 34,066 |
Cash | 76,911 | 106,438 | 114,057 | 138,685 |
Basic Shares | 5,170 | 4,862 | 3,810 | 3,373 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.13 |
2024-06-30 | $0.54 |
2024-03-31 | -$10.50 |
2023-12-31 | -$0.07 |
